PNC27 vs Larazotide acetate
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: PNC-27, p53-HDM2 Disruptor Peptide
PNC-27 is a 32-amino-acid lab-designed peptide that fuses a fragment of the tumor-suppressor protein p53 (residues 12 to 26) to a membrane-penetrating leader sequence. The interesting claim is that it kills cancer cells while leaving normal cells alone, by punching holes in the cancer cell membrane. It is a research compound only, with no approval and no human clinical trials.
Also: Larazotide, AT-1001
Larazotide is an 8-amino-acid oral peptide (GGVLVQPG) designed to tighten the junctions between gut lining cells, aimed at celiac disease. For years it was the furthest-along celiac drug in development and it gets talked about online as a 'leaky gut' or zonulin blocker. The honest story is short: one phase 2b trial found a modest symptom benefit at the lowest dose only, the phase 3 trial was stopped in 2022 when it could not show a clear effect, and the sponsor 9 Meters Biopharma filed for Chapter 7 liquidation in July 2023. It is not approved anywhere.
Key Comparison Insights
- Both peptides belong to the Immune category, suggesting similar primary applications.
- Larazotide acetate has stronger research evidence (Human Trials) compared to PNC27 (Animal Studies).
Detailed Comparison
| Attribute | PNC27 | Larazotide acetate |
|---|---|---|
| Category | Immune | Immune |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | The hook is selectivity. Many cancer cells display the protein HDM-2 (the human version of MDM2) on their outer membrane, while most normal cells keep it tucked inside. PNC-27 carries the part of p53 that normally docks onto HDM-2, so it latches onto that membrane-bound HDM-2 on cancer cells. Once anchored there, the peptide's amphipathic helix-loop-helix structure inserts into the membrane and forms pores, causing the cell to rupture and die by necrosis rather than the slower apoptosis pathway. The peptide has also been reported to disrupt mitochondrial membranes after entering the cell. Normal cells that lack membrane HDM-2 are reported not to bind the peptide and survive, which is the basis for the selectivity claim. | Larazotide is modeled on a fragment of Vibrio cholerae zonula occludens toxin, a region that overlaps with zonulin, the human protein that loosens tight junctions in the gut wall. The idea is that it blocks zonulin signaling and helps tight junctions reassemble, so gluten fragments have a harder time slipping between cells into the tissue underneath, where they trigger the immune reaction in celiac disease. It acts locally in the gut lumen and is not meant to be absorbed. That is a reasonable hypothesis with lab and animal support, but it is worth being clear: larazotide does not stop the immune response to gluten itself, and no human trial proved it protects the gut lining on biopsy. |
| Common Dosing | No human dose - research compound only Not applicable - no human use | 0.5 mg three times daily before meals (trial dose) Three times daily, before meals |
| Administration | IV injection in animal studies - not for human use | Oral capsule taken before meals, alongside a gluten-free diet (not instead of it) |
| Typical Duration | Research protocols only - no human use data | 12 weeks of treatment in the phase 2b trial |
| Best Time to Take | Per research protocol | About 15 minutes before each main meal (trial protocol) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The mechanistic story is backed by real peer-reviewed work, most notably a 2010 paper in PNAS (Sarafraz-Yazdi and colleagues) showing PNC-27 adopts an HDM-2-binding shape and kills cancer cells by binding HDM-2 in their membranes, plus a 2010 study confirming the intact peptide causes tumor cell lysis. Follow-up work, including a 2022 paper in Biomedicines, reinforced the membrane-pore model and selectivity in cell lines and showed transfecting membrane HDM-2 into normal cells makes them vulnerable too. Crucially, all of this is in vitro and in animal models. There are no completed human clinical trials demonstrating safety or anticancer benefit in patients, so any claim that PNC-27 treats cancer in people is not supported. It is a genuinely intriguing preclinical anticancer concept that has not crossed into proven human therapy, and self-experimentation is not justified by the data. | The key human study is a phase 2b trial published in Gastroenterology in 2015 (Leffler and colleagues, NCT01396213). It randomized 342 adults with celiac disease who still had symptoms on a gluten-free diet to 0.5 mg, 1 mg, or 2 mg three times daily or placebo for 12 weeks. Only 0.5 mg met the primary endpoint (symptom score 2.59 vs 2.88), with 26% fewer symptomatic days. The 1 mg and 2 mg doses did nothing measurable, an odd inverse dose response the authors could not explain (peptide aggregation was one guess), and most secondary endpoints missed. Safety looked similar to placebo. The phase 3 CedLara trial (NCT03569007) then tested the same 0.5 mg dose, but in June 2022 an interim analysis showed the number of patients needed to separate drug from placebo was too large to continue, and the trial was terminated. 9 Meters later pointed larazotide at COVID-related conditions such as MIS-C, then filed Chapter 7 in July 2023. We found no active development after that. Bottom line: one positive-ish phase 2b, one stopped phase 3, no approval. |
Frequently Asked Questions: PNC27 vs Larazotide acetate
What is the difference between PNC27 and Larazotide acetate?
PNC27 is a immune peptide that pnc-27 is a 32-amino-acid lab-designed peptide that fuses a fragment of the tumor-suppressor protein p53 (residues 12 to 26) to a membrane-penetrating leader sequence. the interesting claim is that it kills cancer cells while leaving normal cells alone, by punching holes in the cancer cell membrane. it is a research compound only, with no approval and no human clinical trials. Larazotide acetate is a immune peptide that larazotide is an 8-amino-acid oral peptide (ggvlvqpg) designed to tighten the junctions between gut lining cells, aimed at celiac disease. for years it was the furthest-along celiac drug in development and it gets talked about online as a 'leaky gut' or zonulin blocker. the honest story is short: one phase 2b trial found a modest symptom benefit at the lowest dose only, the phase 3 trial was stopped in 2022 when it could not show a clear effect, and the sponsor 9 meters biopharma filed for chapter 7 liquidation in july 2023. it is not approved anywhere. The main differences lie in their mechanisms of action and clinical applications.
Which is better, PNC27 or Larazotide acetate?
Neither is universally "better" - the choice depends on your specific goals. PNC27 is typically used for immune purposes, while Larazotide acetate is used for immune. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can PNC27 and Larazotide acetate be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using PNC27 and Larazotide acetate together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.